title: Oxaliplatin neurotoxicity of sensory transduction in rat proprioceptors.
abstract: Neurotoxic effects of oxaliplatin chemotherapy, including proprioceptive impairments, are debilitating and dose limiting. Here, we sought to determine whether oxaliplatin interrupts normal proprioceptive feedback by impairing sensory transduction of muscle length and force by neurons that are not damaged by dying-back neuropathy. Oxaliplatin was administered over 4 wk to rats in doses that produced systemic changes, e.g., decreased platelets and stunted weight gain, but no significant abnormality in the terminal ends of primary muscle spindle sensory neurons. The absence of neuropathy enabled the determination of whether oxaliplatin caused functional deficits in sensory encoding without the confounding issue of axon death. Rats were anesthetized, and action potentials encoding muscle stretch and contraction were recorded intra-axonally from dorsal roots. In striking contrast with normal proprioceptors, those from oxaliplatin-treated rats typically failed to sustain firing during static muscle stretch. The ability of spindle afferents to sustain and centrally conduct trains of action potentials in response to rapidly repeated transient stimuli, i.e., vibration, demonstrated functional competence of the parent axons. These data provide the first evidence that oxaliplatin causes persistent and selective deficits in sensory transduction that are not due to axon degeneration. Our findings raise the possibility that even those axons that do not degenerate after oxaliplatin treatment may have functional deficits that worsen outcome.
authors: Department of Neuroscience, Cell Biology and Physiology, Wright State University, Dayton, OH 45435, USA.
authors: Katie L
authors: KL
authors: Bullinger
authors: Paul
authors: P
authors: Nardelli
authors: Qingbo
authors: Q
authors: Wang
authors: Mark M
authors: MM
authors: Rich
authors: Timothy C
authors: TC
authors: Cope
references: Muscle Nerve. 2005 Jul;32(1):51-60
references: 15880395
references: J Clin Oncol. 2000 Aug;18(16):2938-47
references: 10944126
references: J Neurophysiol. 1991 Dec;66(6):2155-8
references: 1812241
references: Curr Med Chem. 2006;13(24):2901-7
references: 17073636
references: Clin Pharmacokinet. 2000 Jan;38(1):1-21
references: 10668856
references: J Neurophysiol. 2001 May;85(5):2293-7
references: 11353042
references: Muscle Nerve. 2004 Mar;29(3):387-92
references: 14981738
references: J Clin Oncol. 2002 Aug 15;20(16):3478-83
references: 12177109
references: J Neurosci. 2005 May 11;25(19):4733-42
references: 15888649
references: Cancer Chemother Pharmacol. 2005 Oct;56(4):391-9
references: 15887017
references: Br J Pharmacol. 2005 Dec;146(7):1027-39
references: 16231011
references: Gen Physiol Biophys. 2006 Sep;25(3):263-76
references: 17197725
references: Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68
references: 16806962
references: Brain. 2009 Oct;132(Pt 10):2712-23
references: 19745023
references: Neurotoxicology. 2009 Jul;30(4):677-85
references: 19422847
references: J Clin Invest. 2009 May;119(5):1150-8
references: 19425168
references: Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33
references: 12422305
references: Cancer Treat Rev. 2008 Jun;34(4):368-77
references: 18281158
references: J Physiol. 2010 Jan 1;588(Pt 1):171-85
references: 19917568
references: J Neurophysiol. 2004 May;91(5):2164-71
references: 14695354
references: J Clin Oncol. 2002 Apr 1;20(7):1767-74
references: 11919233
references: Eur J Pharmacol. 2000 Oct 6;406(1):25-32
references: 11011028